Loading...
•
Sep 30, 2020
Palatin Technologies Q1 2021 Earnings Report
Palatin Technologies reported results for the first quarter ended September 30, 2020.
Key Takeaways
Palatin Technologies reported a net loss of $3.9 million for the quarter ended September 30, 2020. The company regained North American rights to Vyleesi® and had $86.6 million in cash and cash equivalents as of September 30, 2020.
Regained North American Rights to Vyleesi® for HSDD with Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021
Phase 2 Clinical Results of PL9643 for the Treatment of Dry Eye Disease on Track for December 2020
$86.6 Million in Cash and Cash Equivalents as of September 30, 2020
Vyleesi® gross sales for the period July 25 to September 30 amounted to $809,100. Recognized $(288,560) in Vyleesi product revenue, net of allowances and accruals